Abstract
Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have